Edgar Filing: LEXICON PHARMACEUTICALS, INC. - Form 4

LEXICON PHARMACEUTICALS, INC. Form 4 February 16, 2016 OMB APPROVAL FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION OMB 3235-0287 Washington, D.C. 20549 Number: Check this box January 31, Expires: if no longer 2005 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF subject to Estimated average **SECURITIES** Section 16. burden hours per Form 4 or response... 0.5 Form 5 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, obligations Section 17(a) of the Public Utility Holding Company Act of 1935 or Section may continue. 30(h) of the Investment Company Act of 1940 See Instruction 1(b). (Print or Type Responses) 1. Name and Address of Reporting Person * 5. Relationship of Reporting Person(s) to 2. Issuer Name and Ticker or Trading COATS LONNEL Issuer Symbol LEXICON PHARMACEUTICALS, (Check all applicable) INC. [LXRX] _X_ Director (Last) (First) (Middle) 3. Date of Earliest Transaction 10% Owner Other (specify X_Officer (give title (Month/Day/Year) below) below) 8800 TECHNOLOGY FOREST 02/11/2016 President and CEO PLACE (Street) 4. If Amendment, Date Original 6. Individual or Joint/Group Filing(Check Filed(Month/Day/Year) Applicable Line) _X_ Form filed by One Reporting Person _ Form filed by More than One Reporting THE WOODLANDS, TX 77381 Person (State) (Zip) (City) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1. Title of 2. Transaction Date 2A. Deemed 3. 4. Securities 5. Amount of 6. Ownership 7. Nature of Security (Month/Day/Year) Execution Date, if TransactionAcquired (A) or Securities Form: Direct Indirect (Instr. 3) any Code Disposed of (D) Beneficially (D) or Indirect Beneficial (Instr. 3, 4 and 5) (Month/Day/Year) (Instr. 8) Owned **(I)** Ownership Following (Instr. 4) (Instr. 4) Reported (A) Transaction(s) or (Instr. 3 and 4) Code V Amount (D) Price Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control number. Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of | 2. | 3. Transaction Date | 3A. Deemed | 4. | 5. Number of | 6. Date Exercisable and | 7. Title and Amount of |
|-------------|------------|---------------------|--------------------|----------|---------------|-------------------------|------------------------|
| Derivative | Conversion | (Month/Day/Year) | Execution Date, if | Transact | iorDerivative | Expiration Date | Underlying Securities |

Edgar Filing: LEXICON PHARMACEUTICALS, INC. - Form 4

| Security (Instr. 3) | or Exercise Price of Derivative Security | | any (Month/Day/Year) | Code (Instr. 8) | Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | r) | (Month/Day/Year) | | (Instr. 3 and 4) | |
|--|---|------------|-------------------------|--------------------|---|-----------------------|--------------------|-----------------|----------------------------|--|
| | | | | Code V | (A) (D) |) Date Exercisable | Expiration Date | Title | Amount Number Shares | |
| Stock Option (Right to Buy) | \$ 8.2 | 02/11/2016 | | A | 134,230 | <u>(1)</u> | 02/11/2026 | Common Stock | 134,23 | |
| Restricted Stock Units (Phantom Stock) | (2) | 02/11/2016 | | A | 33,560 | <u>(3)</u> | <u>(3)</u> | Common Stock | 33,560 | |
| Stock Option (Right to Buy) | \$ 11.76 | | | | | <u>(4)</u> | 07/07/2024 | Common Stock | 121,92 | |
| Stock Option (Right to Buy) | \$ 6.23 | | | | | (5) | 02/05/2025 | Common Stock | 173,37 | |
| Restricted Stock Units (Phantom Stock) | (2) | | | | | <u>(6)</u> | <u>(6)</u> | Common Stock | 43,342 | |

Reporting Owners

| Reporting Owner Name / Address | | Relationships | | | |
|---|--------------------------------|---------------|----------------------|---------|-------|
| FB | Reporting Owner Funct Francess | | 10% Owner | Officer | Other |
| COATS LONNEL 8800 TECHNOLOGY THE WOODLANDS, | Х | | President and CEO | | |
| Signatures | | | | | |
| /s/ Lonnel Coats | 02/16/2016 | | | | |
| <u>**</u> Signature of | Date | | | | |

Reporting Person

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Option vests with respect to 25% of the shares subject to the option on the first anniversary of grant (2/11/2017) and vests 1/48th per month for each month of service thereafter.
- (2) Each restricted stock unit represents a contingent right to receive one share of common stock.
- (3) Restricted stock units vest with respect to 25% of the shares subject to the restricted stock units on February 28, 2017 and vest an additional 25% on February 28 of each of the three succeeding years thereafter.
- (4) Option vests with respect to 25% of the shares subject to the option on the first anniversary of grant (7/7/2015) and vests 1/48th per month for each month of service thereafter.
- (5) Option vests with respect to 25% of the shares subject to the option on the first anniversary of grant (2/5/16) and vests 1/48th per month for each month of service thereafter.
- (6) Restricted stock units vest with respect to 25% of the shares subject to the restricted stock units on February 28, 2016 and vest an additional 25% on February 28 of each of the three succeeding years thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.